Forefronts in Substance Abuse Disorders during Pregnancy, Postpartum, and Pediatrics (FrSADP3)

妊娠期、产后和儿科药物滥用疾病的前沿 (FrSADP3)

• 批准号: 10741269
• 负责人: GERALD SCHATTEN
• 金额: $ 38.29万
• 依托单位: MAGEE-WOMEN'S RES INST AND FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10741269
• 关键词: Address; Advocate; Animals; Birth; Career Choice; Career Mobility; Child; Clinical; Clinical Research; Collaborations; Color; Communities; Dental; Development Plans; Discipline of Nursing; Disease; Doctor of Pharmacy; Doctor of Philosophy; Education; Educational process of instructing; Ensure; Environment; Evaluation; Faculty; Fostering; Future; Goals; Health Insurance Portability and Accountability Act; Hispanic-serving Institution; IACUC; Indigenous American; Individual; Inequity; Institutional Review Boards; Investments; Laws; Leadership; Medical; Mentors; Methods; Minority-Serving Institution; National Institute of Drug Abuse; Participant; Pediatrics; Persons; Pharmaceutical Preparations; Postdoctoral Fellow; Postpartum Period; Pregnancy; Psychologist; Qualifying; Reproducibility; Research; Research Personnel; Research Training; Resources; Risk; Safety; Scientist; Self Administration; Students; Substance abuse problem; Supreme Court Decisions; Therapeutic; Toddler; Training; Underrepresented Minority; United States National Institutes of Health; Universities; Vulnerable Populations; Women' s Health; addiction; career; design; drug withdrawal; education research; ethical, legal, and social implication; experience; healthy lifestyle; innovation; insight; lectures; member; minority trainee; neonate; peer; pregnant; programs; responsible research conduct; skill acquisition; substance use; translational approach

PROGRAM SUMMARY This proposal “Forefronts in Substance Abuse Disorders during Pregnancy, Postpartum and Pediatrics (FrSADP3)” requests its first renewal within NIDA’s Research Education Program. The primary rationale is that there are too few underrepresented minority (URM) clinicians and clinical researchers, too few clinical and research programs investigating substance use (SU) and abuse (SA), and especially, substance abuse disorders (SAD) during pregnancy, postpartum, and in pediatrics (P3); there are far too few new URM trainees for clinical and clinical research careers within the SADP3 fields. Many innovations include optimizing the depth, breadth, and scope of SAD topics of concern during and following pregnancy and the leadership and participation of Indigenous Americans. Our objectives are to train, mentor, provide meaningful research experiences for and help launch the clinical careers of SAD Clinicians and Clinical Scientists (R25 Clinical Trainees). FrSADP3 includes PI and Program Director Gerald Schatten, PhD, at Pitt and Co- I Aimee McRae- Clark, PharmD, BCPP (Addiction Research Leader), with Theresa Cronan, PhD, at SDSU (Facilitator, Psychologist, URM and Women’s Health), Calvin Simerly, PhD, at Pitt (Program Coordinator), and Evan Snyder, MD, PhD, at SBP (Addiction Neonatologist). It is overseen by a Scientific Advisory Board, 40% who are URM faculty. Five Specific Aims: I. Annual FrSADP3 advanced hands-on lab courses, offered at a URM Institution at which we provide conceptual education, expert guided discussions and research training in the methods necessary for studying pregnant people with or at risk for SAD and their neonates, toddlers, and children; relevant animals that self-administer drugs; and the mechanisms of and therapeutic strategies to alleviate the suffering from SADP3, along with research resources available at NIDA and elsewhere. II. Mentored Research into substance use and abuse disorders during pregnancy, postpartum and pediatrics, launched by the participant, together with any FrSADP3 faculty member. III. Encourage trainees’ longer-term Career Planning and gently exploring their self-identified career choices, particularly within the possibilities of them joining NIDA-NIH’s clinical and research workforce. IV. Demystify the changing regulatory oversight requirements in Responsible Conduct for Research (RCR) to ensure full compliance with the NIH’s guidance. V. Unbiased, Quantitative Independent Evaluations to track participants’ careers. The R25’s goals, then, are to provide courses in skills development, mentored addiction research, and ongoing career support resulting in comprehensive, sophisticated training in clinical and translational strategies for addressing the current challenges in addiction during pregnancy, for designing better therapies for the future, and for launching and sustaining successful careers in substance abuse, pregnancy, pediatrics, and related fields. In so doing, FrSADP3 will continue to advance the careers of the most promising clinical scientists and clinicians, with sensitivity for ensuring full diversity in the NIDA workforce.

节目概要 该提案“怀孕、产后和儿科期间药物滥用障碍的前沿 （FrSADP 3）“要求其在NIDA的研究教育计划的第一次更新。主要理由是， 少数民族（URM）临床医生和临床研究人员太少，临床和 调查物质使用（SU）和滥用（SA），特别是物质滥用的研究计划 怀孕期间，产后和儿科（P3）的疾病（SAD）;新的URM学员太少 在SADP 3领域的临床和临床研究事业。许多创新包括优化 在怀孕期间和怀孕后关注的SAD问题的深度、广度和范围，以及领导和 美国原住民的参与。我们的目标是培训，指导，提供有意义的研究 经验，并帮助启动SAD临床医生和临床科学家的临床职业生涯（R25临床 学员）。FrSADP 3包括PI和项目总监Gerald Schatten，博士，在皮特和公司-我Aimee麦克雷- 克拉克，药学博士，BCPP（成瘾研究负责人），与特里萨克罗南，博士，在SDSU（主持人， 心理学家，URM和妇女健康），卡尔文西默利，博士，在皮特（项目协调员），和埃文 斯奈德，医学博士，博士，在SBP（成瘾新生儿学家）。它由一个科学顾问委员会监督，40%的人 是URM的教员。五个具体目标：一。年度FrSADP 3高级实践实验室课程，在 URM机构，我们提供概念教育，专家指导的讨论和研究 培训研究患有SAD或有SAD风险的孕妇及其新生儿所需的方法， 幼儿和儿童;自我给药的相关动物;以及 治疗策略，以减轻从SADP 3的痛苦，随着沿着的研究资源， NIDA和其他地方。二.对怀孕期间药物使用和滥用障碍的研究， 产后和儿科，由参与者与任何FrSADP 3教职员工一起发起。三. 鼓励学员进行长期的职业规划，并温和地探索他们自我确定的职业选择， 特别是在他们加入NIDA-NIH的临床和研究队伍的可能性。四.揭开 不断变化的研究责任行为（RCR）监管要求，以确保充分 遵循国家卫生研究院的指导。五.无偏见的定量独立评价， 参与者的职业生涯。因此，R25的目标是提供技能发展课程， 研究和持续的职业支持，从而在临床和 应对当前妊娠期成瘾挑战的转化战略， 为未来提供更好的治疗方法，并在药物滥用方面开展和维持成功的职业生涯， 妊娠、儿科及相关领域。在这样做的过程中，FrSADP 3将继续推进 最有前途的临床科学家和临床医生，具有确保NIDA劳动力充分多样性的敏感性。

项目成果

Modeling Complex Neurological Diseases with Stem Cells: A Study of Bipolar Disorder.

• DOI: 10.1007/978-3-319-93485-3_12
• 发表时间: 2018
• 期刊: Results and problems in cell differentiation
• 作者: C. Pernia;Neal H. Nathan;B. Tobe;A. Winquist;R. Sidman;Y. Goshima;E. Snyder